Business
Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail
TARRYTOWN, N.Y., Sept. 14, 2021 /PRNewswire/ -- New agreement for 1.4 million doses of REGEN-COV, brings total purchased by the U.S. government to nearly 3
About this update from Regeneron Pharmaceuticals, Inc.
[{"type":"text","content":"TARRYTOWN, N.Y., Sept. 14, 2021 /PRNewswire/ -- \nNew agreement for 1.4 million doses of REGEN-COV, brings total purchased by the U.S. government to nearly 3 million doses\nREGEN-COV currently authorized to treat certain infected patients to reduce risk of hospitalization or death from COVID-19, and for post-exposure prophylaxis for close contacts of infected individuals\nRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase 1.4 million additional doses of REGEN-COV (casirivimab and imdevimab). The government will continue to provide REGEN-COV at no cost to patients.\n\"More than a year and a half into this pandemic, too many people are still being hospitalized and dying due to COVID-19,\" said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. \"While vaccination remains the first line of defense to decrease the burden of COVID-19, REGEN-COV is a key tool that reduces the risk of hospitalization or death by 70% in high-risk individuals when given early in the course of the infection. Recently there has been greater demand for REGEN-COV, and we will provide additional doses to the U.S. government as quickly as possible.\"\nUnder the new agreement, Regeneron will supply an additional 1.4 million 1,200 mg doses of REGEN-COV to the U.S. government by January 31, 2022, at a cost of $2,100 per dose. This new agreement follows two earlier agreements with the U.S. government announced in July 2020 and January 2021.\nREGEN-COV is an investigational medicine authorized by the U.S. Food and Drug Administration (FDA) under an emergency use authorization to treat people who are at high risk of serious consequences from COVID-19 infection who are either already infected (non-hospitalized) or in certain post-exposure prophylaxis settings. \nIn addition, the robust REGEN-COV development program has reported positive Phase 3 trial results across the spectrum of COVID-19 infection, from prevention to hospitalization:\nPrevention of symptomatic infection in asymptomatic household contacts (both uninfected and infected) of SARS-CoV-2 infected individuals Treatment of non-hospitalized patients already infected with SARS-CoV-2 Treatment of certain patients hospitalized due to COVID-19 infection, i...